Neurol. praxi. 2019;20(4):288-290 | DOI: 10.36290/neu.2019.155
Significance of multiple sclerosis early treatment
- Neurologická klinika a JLF UK a UNM, Martin
Multiple sclerosis is a chronic disorder, which primarily affects young adults. Timing of treatment determines further evolution of
the disorder and positively influences quality of life. The work brings new insides on diagnostics and treatment of the disorder.
Keywords: multiple sclerosis, early treatment, patomechanisms, diagnostic criteria
Received: June 25, 2018; Accepted: July 18, 2018; Prepublished online: July 18, 2018; Published: September 1, 2019 Show citation
References
- Buc M. Sclerosis multiplex - úloha regulačných T-lymfocytov v patogenéze a biologickej liečbe choroby. Cesk Slov Neurol N 2013; 76/109(3): 293-299.
- Daňová M, Klímová E. Porovnanie validity diagnostických kritérií sclerosis multiplex 2005 vs 2010 s aspektom včasnej diagnostiky. Cesk Slov Neurol N 2014; 77/110(2): 181-185.
- Donath V. Nová perspektívna liečba sclerosis multiplex. Neurol. Prax 2014; 15(2): 57-59.
- Edan G, LePage E. Mitoxantron to treat multiple sclerosis, in Multiple Sclerosis Therapeutics. Cambridge University Press 2011.
Go to original source... - Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008 Mar; 131(Pt 3): 808-17. Go to original source...
Go to PubMed... - Havrdova E, a kol. Roztroušená skleróza. Mladá Fronta 2013.
- Hochmuth L. B lymfocyty ako cieľ v liečbe sclerosis multiplex. Neurol. prax 2017; 18(3): 186-189. Go to original source...
- Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol 2010; 10(11): 1026-1034. Go to original source... Go to PubMed...
- Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. 2001; 7(3): 115-121. Go to original source... Go to PubMed...
- Macrez R, Stys PK, Vivien D, Lipton SA, Docagne F. Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities. Lancet Neurol 2016; 15(10): 1089-102. Go to original source... Go to PubMed...
- Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Bellachew S, Garren H, Mairon N, Chin P, Wolinsky JS, Oratorio clinical investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Eng J Med 2017; 376(3): 209-20. Go to original source... Go to PubMed...
- Polman CH, Reingold SC, Banwell B, Sandberg-Wollheim M,Clanet M, Cohen JA, Fillipi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, Thompson AJ, O'Connor F, Sandberg-Wolheim M, Thomson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292-302. Go to original source... Go to PubMed...
- Rio J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Current Opinion in Neurology 2011; 24: 230-237. Go to original source... Go to PubMed...
- Rodriguez M. Advances in multiple sclerosis and experimental demyelinating disease. Springer 2008. Go to original source...
- Shaked I, Hanna R, Shaked H, Chodaczek G, Nowyhed NH,Tweet G, Tacke R, Basat AB, Mikulski Z, Togher S, Miller J, Blatchley A, Salek-Ardacani S, Darvas M, Kaikkonen MU, Thomas GD, Lai-Wing-Sun S, Rezk A, Bar-Or A, Glass CK, Bandukwala H, Hedrick CC. Transcription factor Nr4a1 couples sympathetic and in-flammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nature Immunol-ogy. 2015; DOI: 10.1038/ni.3321. Go to original source... Go to PubMed...
- Tan SL, Liao C, Lucas MC, Stevenson C, DeMartino JA. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic per-spectives. Pharmacol Ther 2013; 138(2): 294-309. Go to original source... Go to PubMed...
- Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-173. Go to original source... Go to PubMed...
- Tintoré M. Rationale for early intervention with immunomodulatory treatments. J Neurol 2008 Mar; 255 Suppl 1:37-43. doi: 10.1007/s00415-008-1006-4. Go to original source... Go to PubMed...
- Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. Journal of neurology 2008; 255(10): 1449-1463. Go to original source... Go to PubMed...